脂蛋白(a)作为肝细胞癌残余肝功能的潜在标志物。
Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.
作者信息
Uccello Mario, Malaguarnera Giulia, Pelligra Elisa M, Biondi Antonio, Basile Francesco, Motta Massimo
机构信息
Departments of Senescence, Urological & Neurological Sciences, University of Catania, Catania, Italy.
出版信息
Indian J Med Paediatr Oncol. 2011 Apr;32(2):71-5. doi: 10.4103/0971-5851.89775.
Abstract
The residual liver function is a major clinical index in hepatocellular carcinoma (HCC) patients. As the liver plays a crucial role in lipid and lipoprotein metabolism, the significant impairment of the hepatic function occurring during chronic liver diseases, such as HCC, can influence plasma lipoprotein profiles. Although, lipoprotein(a) (Lp(a)) circulating concentrations are mostly determined by genetic factors, in the majority of reports they have shown a correlation with the hepatic status and a significant decrease in HCC and liver cirrhosis patients than among the controls. In such a way, Lp(a) may represent a new additional and useful marker for a more complete assessment and monitoring of the liver function in patients with HCC and liver cirrhosis. Further studies are needed in order to evaluate the clinical significance of Lp(a) in HCC.
摘要
残余肝功能是肝细胞癌（HCC）患者的一项主要临床指标。由于肝脏在脂质和脂蛋白代谢中起着关键作用，慢性肝病（如HCC）期间发生的肝功能显著损害会影响血浆脂蛋白谱。尽管脂蛋白(a)（Lp(a)）的循环浓度大多由遗传因素决定，但在大多数报告中，它们显示出与肝脏状态相关，且HCC和肝硬化患者的Lp(a)浓度比对照组显著降低。因此，Lp(a)可能是一种新的、额外的有用标志物，用于更全面地评估和监测HCC和肝硬化患者的肝功能。为了评估Lp(a)在HCC中的临床意义，还需要进一步的研究。
相似文献
1
Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.
Indian J Med Paediatr Oncol. 2011 Apr;32(2):71-5. doi: 10.4103/0971-5851.89775.
2
Lipoprotein (a) behaviour in patients with hepatocellular carcinoma.
Minerva Med. 2001 Oct;92(5):301-5.
3
Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):25-8.
4
Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.
Lipids Health Dis. 2008 Jul 24;7:25. doi: 10.1186/1476-511X-7-25.
5
Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.
Oncol Lett. 2017 May;13(5):3457-3464. doi: 10.3892/ol.2017.5890. Epub 2017 Mar 22.
6
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
J Hepatol. 2017 Jul;67(1):65-71. doi: 10.1016/j.jhep.2017.01.033. Epub 2017 Feb 10.
7
Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity.
World J Gastroenterol. 2018 Jan 21;24(3):415-423. doi: 10.3748/wjg.v24.i3.415.
8
Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma.
PLoS One. 2015 Oct 8;10(10):e0140066. doi: 10.1371/journal.pone.0140066. eCollection 2015.
9
Clinical significance of abnormal lipoprotein patterns in liver diseases.
Int J Mol Med. 2005 Apr;15(4):655-60.
10
Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocellular carcinoma.
J Pak Med Assoc. 1992 Nov;42(11):260-3.
引用本文的文献
1
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.
Eur Heart J Open. 2024 Aug 31;4(5):oeae064. doi: 10.1093/ehjopen/oeae064. eCollection 2024 Sep.
2
Lipid profile and risk of ovarian tumours: a meta-analysis.
BMC Cancer. 2020 Mar 12;20(1):200. doi: 10.1186/s12885-020-6679-9.
3
Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis.
Lipids Health Dis. 2018 Nov 6;17(1):248. doi: 10.1186/s12944-018-0898-y.
4
D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis.
Clin Exp Gastroenterol. 2018 Oct 3;11:373-380. doi: 10.2147/CEG.S172663. eCollection 2018.
5
Lipoprotein (a): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection.
Onco Targets Ther. 2018 Sep 17;11:5917-5924. doi: 10.2147/OTT.S164273. eCollection 2018.
6
Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: A protein-based hepatocellular carcinoma-associated study.
Indian J Med Res. 2018 Apr;147(4):361-368. doi: 10.4103/ijmr.IJMR_1358_16.
7
Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels.
J Thorac Dis. 2017 Aug;9(8):2332-2336. doi: 10.21037/jtd.2017.08.67.
8
Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis.
Nucleic Acids Res. 2016 Jul 8;44(12):5529-39. doi: 10.1093/nar/gkw462. Epub 2016 May 23.
9
Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Am J Transl Res. 2015 Nov 15;7(11):2510-8. eCollection 2015.
10
Centenarians and supercentenarians: a black swan. Emerging social, medical and surgical problems.
BMC Surg. 2012;12 Suppl 1(Suppl 1):S36. doi: 10.1186/1471-2482-12-S1-S36. Epub 2012 Nov 15.
本文引用的文献
1
Liver functional reserve estimation: state of the art and relevance to local treatments.
Oncology. 2010 Jul;78 Suppl 1:131-4. doi: 10.1159/000315241. Epub 2010 Jul 8.
2
The physiopathology of lipoprotein (a).
Front Biosci (Schol Ed). 2010 Jun 1;2(3):866-75. doi: 10.2741/s107.
3
Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis.
World J Gastroenterol. 2010 Mar 21;16(11):1397-401. doi: 10.3748/wjg.v16.i11.1397.
4
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
N Engl J Med. 2009 Dec 24;361(26):2518-28. doi: 10.1056/NEJMoa0902604.
5
Liver functional reserve estimation: state of the art and relevance for local treatments: the Eastern perspective.
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):380-4. doi: 10.1007/s00534-009-0229-9. Epub 2009 Oct 29.
6
Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence.
Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):467-70. doi: 10.1510/icvts.2009.208843. Epub 2009 Jun 29.
7
Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):46-9.
8
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.
Nat Genet. 2009 Mar;41(3):283-5. doi: 10.1038/ng.314. Epub 2009 Feb 8.
9
Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.
Lipids Health Dis. 2008 Jul 24;7:25. doi: 10.1186/1476-511X-7-25.
10
Genetics of cholesterol and lipoprotein metabolism.
Recent Pat Cardiovasc Drug Discov. 2007 Nov;2(3):195-204. doi: 10.2174/157489007782418937.
Zotero 插件